BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:OBX-115 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of OBX-115\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05470283-2650@assetmemo.bio
DTSTAMP:20261121T005855Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:OBX-115: Phase 1 readout est. (NCT05470283)
DESCRIPTION:OBX-115\, phase 1\, Melanoma.\nStudy: Phase I\, Open-Label\, St
 udy of Tumor Infiltrating Lymphocytes Engineered With Membrane Bound IL15 
 Plus Acetazolamide in Adult Patients With Metastatic Melanoma\nEstimated p
 rimary completion: 1 April 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/obx-115#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT05470283
URL:https://assetmemo.bio/drug/obx-115#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06060613-2650@assetmemo.bio
DTSTAMP:20261121T005855Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:OBX-115: Phase 1/2 readout est. (NCT06060613)
DESCRIPTION:OBX-115\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: Safet
 y and Efficacy of OBX-115 in Advanced Solid Tumors\nEstimated primary comp
 letion: 30 June 2029. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /obx-115#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT06060613
URL:https://assetmemo.bio/drug/obx-115#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
